BioCryst Pharma Analyst Ratings
BioCryst Pharma Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/20/2023 | 86.92% | JP Morgan | → $10 | Reinstates | → Overweight |
| 11/06/2023 | 124.3% | Needham | → $12 | Reiterates | Buy → Buy |
| 09/25/2023 | 86.92% | RBC Capital | → $10 | Reiterates | Outperform → Outperform |
| 09/18/2023 | 86.92% | RBC Capital | $9 → $10 | Upgrades | Sector Perform → Outperform |
| 08/04/2023 | 68.22% | RBC Capital | $8 → $9 | Maintains | Sector Perform |
| 08/04/2023 | 105.61% | Jefferies | → $11 | Upgrades | Hold → Buy |
| 08/04/2023 | 460.75% | HC Wainwright & Co. | → $30 | Reiterates | Buy → Buy |
| 08/03/2023 | 124.3% | Needham | $14 → $12 | Reiterates | → Buy |
| 07/13/2023 | 86.92% | B of A Securities | → $10 | Upgrades | Neutral → Buy |
| 05/04/2023 | 68.22% | RBC Capital | → $9 | Reiterates | → Sector Perform |
| 05/04/2023 | 161.68% | Needham | → $14 | Reiterates | → Buy |
| 04/20/2023 | 86.92% | Evercore ISI Group | $13 → $10 | Maintains | Outperform |
| 04/20/2023 | 161.68% | Needham | → $14 | Reiterates | → Buy |
| 03/14/2023 | 86.92% | RBC Capital | → $10 | Reiterates | → Sector Perform |
| 02/22/2023 | 199.07% | JMP Securities | → $16 | Reiterates | → Market Outperform |
| 02/22/2023 | 161.68% | Needham | → $14 | Upgrades | Hold → Buy |
| 02/22/2023 | 460.75% | HC Wainwright & Co. | → $30 | Reiterates | → Buy |
| 11/02/2022 | 199.07% | Evercore ISI Group | → $16 | Upgrades | In-Line → Outperform |
| 11/02/2022 | 142.99% | RBC Capital | $14 → $13 | Maintains | Sector Perform |
| 08/08/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/05/2022 | 161.68% | Barclays | $12 → $14 | Maintains | Equal-Weight |
| 08/05/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 08/05/2022 | 161.68% | Evercore ISI Group | → $14 | Downgrades | Outperform → In-Line |
| 04/18/2022 | 142.99% | Barclays | $22 → $13 | Downgrades | Overweight → Equal-Weight |
| 04/12/2022 | 161.68% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
| 04/11/2022 | 161.68% | B of A Securities | → $14 | Downgrades | Buy → Neutral |
| 04/11/2022 | 199.07% | Oppenheimer | $20 → $16 | Maintains | Outperform |
| 12/10/2021 | 199.07% | Oppenheimer | → $16 | Initiates Coverage On | → Outperform |
| 11/04/2021 | 161.68% | RBC Capital | $16 → $14 | Maintains | Sector Perform |
| 11/04/2021 | 217.76% | Barclays | $21 → $17 | Maintains | Overweight |
| 08/06/2021 | — | Jefferies | Downgrades | Buy → Hold | |
| 08/06/2021 | 199.07% | RBC Capital | $13 → $16 | Maintains | Sector Perform |
| 08/06/2021 | 329.91% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
| 08/06/2021 | 292.52% | Barclays | $20 → $21 | Maintains | Overweight |
| 08/06/2021 | 460.75% | HC Wainwright & Co. | $18 → $30 | Maintains | Buy |
| 08/03/2021 | 292.52% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 03/24/2021 | 255.14% | HC Wainwright & Co. | $14 → $19 | Maintains | Buy |
| 01/22/2021 | 68.22% | RBC Capital | $7 → $9 | Maintains | Sector Perform |
| 12/07/2020 | 161.68% | HC Wainwright & Co. | $13 → $14 | Maintains | Buy |
| 11/24/2020 | 124.3% | Evercore ISI Group | → $12 | Initiates Coverage On | → Outperform |
| 06/17/2020 | — | BTIG | Initiates Coverage On | → Neutral | |
| 05/05/2020 | 30.84% | Barclays | $4 → $7 | Upgrades | Equal-Weight → Overweight |
| 11/15/2019 | — | B of A Securities | Upgrades | Neutral → Buy | |
| 05/24/2019 | -15.89% | RBC Capital | $16 → $4.5 | Downgrades | Outperform → Sector Perform |
| 04/02/2019 | 49.53% | Barclays | $6 → $8 | Maintains | Equal-Weight |
| 04/02/2019 | 236.45% | JMP Securities | $16 → $18 | Maintains | Market Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/20/2023 | 86.92% | 摩根大通 | → 10 美元 | 恢复 | → 超重 |
| 11/06/2023 | 124.3% | 尼德姆 | → 12 美元 | 重申 | 购买 → 购买 |
| 09/25/2023 | 86.92% | 加拿大皇家银行资本 | → 10 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 09/18/2023 | 86.92% | 加拿大皇家银行资本 | 9 美元 → 10 美元 | 升级 | 行业表现 → 跑赢大盘 |
| 08/04/2023 | 68.22% | 加拿大皇家银行资本 | 8 美元 → 9 美元 | 维护 | 行业表现 |
| 08/04/2023 | 105.61% | 杰富瑞集团 | → 11 美元 | 升级 | 持有 → 买入 |
| 08/04/2023 | 460.75% | HC Wainwright & Co. | → 30 美元 | 重申 | 购买 → 购买 |
| 08/03/2023 | 124.3% | 尼德姆 | 14 美元 → 12 美元 | 重申 | → 购买 |
| 07/13/2023 | 86.92% | B of A 类证券 | → 10 美元 | 升级 | 中性 → 买入 |
| 05/04/2023 | 68.22% | 加拿大皇家银行资本 | → 9 美元 | 重申 | → 行业表现 |
| 05/04/2023 | 161.68% | 尼德姆 | → 14 美元 | 重申 | → 购买 |
| 04/20/2023 | 86.92% | Evercore ISI 集团 | 13 美元 → 10 美元 | 维护 | 跑赢大盘 |
| 04/20/2023 | 161.68% | 尼德姆 | → 14 美元 | 重申 | → 购买 |
| 03/14/2023 | 86.92% | 加拿大皇家银行资本 | → 10 美元 | 重申 | → 行业表现 |
| 02/22/2023 | 199.07% | JMP 证券 | → 16 美元 | 重申 | → 市场跑赢大盘 |
| 02/22/2023 | 161.68% | 尼德姆 | → 14 美元 | 升级 | 持有 → 买入 |
| 02/22/2023 | 460.75% | HC Wainwright & Co. | → 30 美元 | 重申 | → 购买 |
| 11/02/2022 | 199.07% | Evercore ISI 集团 | → 16 美元 | 升级 | 盘中 → 跑赢大盘 |
| 11/02/2022 | 142.99% | 加拿大皇家银行资本 | 14 美元 → 13 美元 | 维护 | 行业表现 |
| 08/08/2022 | — | 奥本海默 | 降级 | 跑赢大盘 → 表现 | |
| 08/05/2022 | 161.68% | 巴克莱 | 12 美元 → 14 美元 | 维护 | 重量相等 |
| 08/05/2022 | — | 奥本海默 | 降级 | 跑赢大盘 → 表现 | |
| 08/05/2022 | 161.68% | Evercore ISI 集团 | → 14 美元 | 降级 | 跑赢大盘 → 在线 |
| 04/18/2022 | 142.99% | 巴克莱 | 22 美元 → 13 美元 | 降级 | 超重 → 重量相等 |
| 04/12/2022 | 161.68% | 加拿大皇家银行资本 | 16 美元 → 14 美元 | 维护 | 行业表现 |
| 2022 年 11 月 4 日 | 161.68% | B of A 类证券 | → 14 美元 | 降级 | 买入 → 中性 |
| 2022 年 11 月 4 日 | 199.07% | 奥本海默 | 20 美元 → 16 美元 | 维护 | 跑赢大盘 |
| 12/10/2021 | 199.07% | 奥本海默 | → 16 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2021 年 4 月 11 日 | 161.68% | 加拿大皇家银行资本 | 16 美元 → 14 美元 | 维护 | 行业表现 |
| 2021 年 4 月 11 日 | 217.76% | 巴克莱 | 21 美元 → 17 美元 | 维护 | 超重 |
| 08/06/2021 | — | 杰富瑞集团 | 降级 | 买入 → 持有 | |
| 08/06/2021 | 199.07% | 加拿大皇家银行资本 | 13 美元 → 16 美元 | 维护 | 行业表现 |
| 08/06/2021 | 329.91% | JMP 证券 | 22 美元 → 23 美元 | 维护 | 市场表现跑赢大盘 |
| 08/06/2021 | 292.52% | 巴克莱 | 20 美元 → 21 美元 | 维护 | 超重 |
| 08/06/2021 | 460.75% | HC Wainwright & Co. | 18 美元 → 30 美元 | 维护 | 买 |
| 08/03/2021 | 292.52% | 坎托·菲茨杰拉德 | → 21 美元 | 启动覆盖范围开启 | → 超重 |
| 2021 年 3 月 24 日 | 255.14% | HC Wainwright & Co. | 14 美元 → 19 美元 | 维护 | 买 |
| 2021 年 1 月 22 日 | 68.22% | 加拿大皇家银行资本 | 7 美元 → 9 美元 | 维护 | 行业表现 |
| 12/07/2020 | 161.68% | HC Wainwright & Co. | 13 美元 → 14 美元 | 维护 | 买 |
| 11/24/2020 | 124.3% | Evercore ISI 集团 | → 12 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2020 年 6 月 17 日 | — | BTIG | 启动覆盖范围开启 | → 中立 | |
| 05/05/2020 | 30.84% | 巴克莱 | 4 美元 → 7 美元 | 升级 | 重量相等 → 超重 |
| 11/15/2019 | — | B of A 类证券 | 升级 | 中性 → 买入 | |
| 05/24/2019 | -15.89% | 加拿大皇家银行资本 | 16 美元 → 4.5 美元 | 降级 | 跑赢大盘 → 行业表现 |
| 04/02/2019 | 49.53% | 巴克莱 | 6 美元 → 8 美元 | 维护 | 重量相等 |
| 04/02/2019 | 236.45% | JMP 证券 | 16 美元 → 18 美元 | 维护 | 市场表现跑赢大盘 |
What is the target price for BioCryst Pharma (BCRX)?
BioCryst Pharma（BCRX）的目标价格是多少？
The latest price target for BioCryst Pharma (NASDAQ: BCRX) was reported by JP Morgan on November 20, 2023. The analyst firm set a price target for $10.00 expecting BCRX to rise to within 12 months (a possible 86.92% upside). 17 analyst firms have reported ratings in the last year.
摩根大通于2023年11月20日公布了BioCryst Pharma（纳斯达克股票代码：BCRX）的最新目标股价。该分析公司将目标股价定为10.00美元，预计BCRX将在12个月内升至12个月内（可能上涨86.92％）。去年有17家分析公司公布了评级。
What is the most recent analyst rating for BioCryst Pharma (BCRX)?
分析师对BioCryst Pharma（BCRX）的最新评级是多少？
The latest analyst rating for BioCryst Pharma (NASDAQ: BCRX) was provided by JP Morgan, and BioCryst Pharma their overweight rating.
摩根大通对BioCryst Pharma（纳斯达克股票代码：BCRX）的最新分析师评级由摩根大通提供，BioCryst Pharma提供了增持评级。
When is the next analyst rating going to be posted or updated for BioCryst Pharma (BCRX)?
BioCryst Pharma（BCRX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on November 20, 2023 so you should expect the next rating to be made available sometime around November 20, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与BioCryst Pharma的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。BioCryst Pharma的最新评级是在2023年11月20日公布的，因此您应该预计下一个评级将在2024年11月20日左右公布。
Is the Analyst Rating BioCryst Pharma (BCRX) correct?
分析师对 BioCryst Pharma (BCRX) 的评级正确吗？
While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a with a price target of $0.00 to $10.00. The current price BioCryst Pharma (BCRX) is trading at is $5.35, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的BioCryst Pharma（BCRX）评级为A，目标股价为0.00美元至10.00美元。BioCryst Pharma（BCRX）目前的交易价格为5.35美元，在分析师的预测区间内。